Pharmaceutical Research and Manufacturers of America: Difference between revisions
| Line 20: | Line 20: | ||
==Issues== |
==Issues== |
||
| ⚫ | |||
{{main | Doha Declaration}} |
|||
===Medicare part D=== |
|||
PhRMA has worked to minimize the effect of the [[Doha Declaration]] by the Doha round of negotiations. The Doha Declaration issued in November 2001, indicated that TRIPs should not prevent states from dealing with public health crises. The health crises specifically addressed by the declaration include the AIDS epidemic.<ref>http://en.wikipedia.org/wiki/Agreement_on_Trade-Related_Aspects_of_Intellectual_Property_Rights#Controversy</ref> |
|||
{{Main article|Medicare Part D}} |
|||
{{Expand section}} |
|||
===Patient Protection and Affordable Care Act=== |
|||
===Depression in the workplace=== |
|||
{{Main article|Patient Protection and Affordable Care Act}} |
|||
In June 2004, PhRMA teamed up with the [[U.S. Chamber of Commerce]] and the [[American Psychiatric Association]] "to demonstrate the cost of [[Clinical depression|depression]] in the workplace and to show employers that treating affected workers would improve the bottom line." The three groups endorsed a "depression calculator," which allows employers to estimate the effect of untreated depression on their company's profits, through absenteeism and low productivity. The calculator also figures "how much the business would save if employees were treated."<ref>{{cite web|url=http://www.depressioncalculator.com/Welcome.asp|title=Productivity Impact Model: Calculating the Impact of Depression in the Workplace and the Benefits of Treatment|publisher=PhRMA|accessdate=2007-05-14}}</ref> The Arizona-based "health-care consulting firm" The HSM Group organized the calculator's public "introduction." At the press conference unveiling the calculator, PhRMA's senior vice president for policy, research and strategic planning, Richard Smith, said: "A depressed employee is less productive or absent for 30 to 50 days a year. ... The person's medical costs are $2,000 to $3,000 more than other employees." |
|||
{{Expand section}} |
|||
===Intellectual property=== |
===Intellectual property=== |
||
| ⚫ | Every year, PhRMA makes substantial efforts with regard to [[Special 301 Report]] issued by the [[Office of the [United States Trade Representative]] on the enforcement of intellectual property laws abroad.{{cn}} PhRMA's recommendations for the Special 301 Report in 2009 were especially critical of the Philippines for "breaking patents" and failing to abide by the [[Agreement on Trade-Related Aspects of Intellectual Property Rights]], commonly known as TRIPS.<ref name="RP">{{cite news |title= US lobby wants RP penalized for cheaper drugs law |author= Jessica Anne D. Hermosa |newspaper=BusinessWorld |date=4 March 2009 |accessdate=29 April 2011}}</ref> |
||
PhRMA argues that since biopharmaceutical research companies operate under an especially difficult business model where they must make very large investments in research and development 10 to 15 years before their products reach the market, and that these investments are greatly facilitated by the protection of [[intellectual property]]. PhRMA argues that there are three key factors that determine the effectiveness of an intellectual property regime. Promoting "fair and effective incentives for innovation;" giving "innovators certainty regarding their rights;" and offering "strong enforcement tools for defending infringed patents." <ref name="IP">{{cite web |url=http://www.phrma.org/issues/intellectual-property |title=Intellectual Property |publisher=PhRMA |accessdate=29 April 2011}}</ref> |
|||
| ⚫ | |||
PhRMA has worked to minimize the effect of the November 2001 [[Doha Declaration]] by the Doha round of negotiations.{{cn}} |
|||
| ⚫ | Every year, PhRMA makes substantial efforts with regard to [[Special 301 Report]] issued by the [[Office of the [United States Trade Representative]] on the enforcement of intellectual property laws abroad. PhRMA's recommendations for the Special 301 Report in 2009 were especially critical of the Philippines for "breaking patents" and failing to abide by the [[Agreement on Trade-Related Aspects of Intellectual Property Rights]], commonly known as TRIPS.<ref name="RP">{{cite news |title= US lobby wants RP penalized for cheaper drugs law |
||
|author= Jessica Anne D. Hermosa |newspaper=BusinessWorld |date=4 March 2009 |accessdate=29 April 2011}}</ref> |
|||
==Programs for patients== |
==Programs for patients== |
||
Revision as of 00:49, 30 April 2011
Pharmaceutical Research and Manufacturers of America (PhRMA), founded in 1958, is a trade group representing the pharmaceutical research and biotechnology companies in the United States. PhRMA's stated mission is advocacy for public policies that encourage the discovery of new medicines for patients by pharmaceutical and biotechnology research companies. PhRMA's current CEO is John J. Castellani.
Mission
On its website, PhRMA states its "mission is winning advocacy for public policies that encourage the discovery of life-saving and life-enhancing new medicines for patients by pharmaceutical / biotechnology research companies. To accomplish this mission, PhRMA is dedicated to achieving in Washington, D.C., the states and the world:[1]
- "Broad patient access to safe and effective medicines through a free market, without price controls,
- "Strong intellectual property incentives, and
- "Transparent, efficient, regulation and a free flow of information to patients."
Leadership
Chris Viehbacher
Chris Viehbacher is the Chairman of PhRMA's board of directors. Since 2008 Viehbacher has also served as CEO of Sanofi-Aventis. He was born on 26 March 1960. He holds both German and Canadian nationalities. Viebacher is a certified public accountant. He graduated from Queens University in Canada.[2]
John J. Castellani
John J. Castellani is President and CEO of PhRMA. Castellani has promised that PhRMA will continue to support healthcare reform efforts in the United States and abroad. Specifically, PhRMA will focus on helping to successfully implement and improve the health reform legislation passed in 2010 under President Obama with a particular emphasis on rewarding innovation.[3]Jeffrey Kindler, the chairman of Pfizer and former chairman of PhRMA, when commenting on Castellani's move from the Business Roundtable to PhRMA, said, “John is the gold standard, and I’m extremely pleased that he will lead our team."[4] Mr. Castellani succeeds Billy Tauzin, a former Republican congressman from Louisiana.[4]
Issues
Medicare part D
![[icon]](/wiki/File:Wiki_letter_w_cropped.svg){kind=small} | This section needs expansion. You can help by adding to it. |
Patient Protection and Affordable Care Act
| This section needs expansion. You can help by adding to it. |
Intellectual property
Every year, PhRMA makes substantial efforts with regard to Special 301 Report issued by the [[Office of the [United States Trade Representative]] on the enforcement of intellectual property laws abroad.[citation needed] PhRMA's recommendations for the Special 301 Report in 2009 were especially critical of the Philippines for "breaking patents" and failing to abide by the Agreement on Trade-Related Aspects of Intellectual Property Rights, commonly known as TRIPS.[5]
Doha
PhRMA has worked to minimize the effect of the November 2001 Doha Declaration by the Doha round of negotiations.[citation needed]
Programs for patients
SMARxT Disposal
SMARxT Disposal is a joint program run by the U.S. Fish and Wildlife Service, the American Pharmacists Association, and PhRMA to encourage consumers to properly dispose of unused medicines in order to avoid harm to the environment.[6]
Partnership for Prescription Assistance
The Partnership for Prescription Assistance is a program by PhRMA and its member companies that connects patients in-need with information on low-cost and free prescription medication.[6]
Members
Some prominent members of PhRMA include the following. A full list of members is available at the PhRMA website.[7]
- AstraZeneca
- Bayer
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Eli Lilly and Company
- Genzyme Corporation
- GlaxoSmithKline
- Merck
- Novartis
- Pfizer
- Sanofi-Aventis
See also
- European Federation of Pharmaceutical Industries and Associations (EFPIA)
- Food and Drug Administration (FDA, USA)
- International Federation of Pharmaceutical Manufacturers Associations (IFPMA)
- International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)
- Japan Pharmaceutical Manufacturers Association (JPMA)
- Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme
- SAFE-BioPharma Association (SAFE)
References
- ^ "Mission Statement". PhRMA. Retrieved 2011-02-06.
- ^ "Chris Viehbacher Biography". Pharmaceutical Research and Manufacturers of America. Retrieved 6 April 2011.
- ^ whorunsgov.com
- ^ a b Pharmaceutical group shifts tone with new pick for president, by N.C. Alzenman and Dan Eggen, The Washington Post, 14 July 2010
- ^ Jessica Anne D. Hermosa (4 March 2009). "US lobby wants RP penalized for cheaper drugs law". BusinessWorld.
{{cite news}}:|access-date=requires|url=(help) - ^ a b "Patient Resrouces". Pharmaceutical Research and Manufacturers of America. Retrieved 6 April 2011.
- ^ [1]